Evidence map›Paper›PMID 37107001›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Modulation of the Acute Inflammatory Response Induced by the

Victoria Cazanga, Cristina Palma, Tomás Casanova, Daniela Rojas, Karin Barrera, Cristhian Valenzuela, Aracelly Acevedo, Gabriel Ascui-Gac, Tamara Pérez-Jeldres, Rubén Pérez-Fernández

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Antimicrobial Activity ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. FXR deletion attenuates intestinal barrier dysfunction in murine acute intestinal inflammation.American journal of physiology. Gastrointestinal and liver physiology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Victoria CazangaPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Cristina PalmaPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Tomás CasanovaPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Daniela RojasVeterinary Pathology Laboratory, Department of Pathology and Preventive Medicine, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Karin BarreraPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Cristhian ValenzuelaPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Aracelly AcevedoPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.
Gabriel Ascui-GacCenter for Autoimmunity and Inflammation, La Jolla Institute for Immunology, California University, San Diego, CA 92182, USA.ORCID 0000-0001-6837-3194
Tamara Pérez-JeldresDepartment of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
Rubén Pérez-FernándezPharmacology Laboratory, Department of Clinical Sciences, Faculty of Veterinary Sciences, Universidad de Concepción, Chillan 3820572, Chile.ORCID 0000-0003-2846-3165
University of Concepción · CLLa Jolla Institute for Immunology · USPontificia Universidad Católica de Chile · CL

Funding

Agencia Nacional de Investigación y Desarrollo FONDECYT 1201449
6 · The paper itself

Abstract

backgroundExperimental reports have demonstrated that florfenicol (FFC) exerts potent anti-inflammatory effects, improving survival in a murine endotoxemia model. Considering the anti-inflammatory and immunomodulatory properties of pentoxifylline (PTX) as an adjuvant to enhance the efficacy of antibiotics, the anti-inflammatory effects of the interaction FFC/PTX over the

methodsTwenty-five clinically healthy New Zealand rabbits (3.8 ± 0.2 kg body weight: bw), were distributed into five experimental groups. Group 1 (control): treated with 1 mL/4 kg bw of 0.9% saline solution (SS) intravenously (IV). Group 2 (LPS): treated with an IV dose of 5 µg/kg of LPS. Group 3 (pentoxifylline (PTX) + LPS): treated with an oral dose of 30 mg/kg PTX, followed by an IV dose of 5 µg/kg of LPS 45 min after PTX. Group 4 (Florfenicol (FFC) + LPS): treated with an IM dose of 20 mg/kg of FFC, followed by an IV dose of 5 µg/kg of LPS 45 min after FFC administration. Group 5 (PTX + FFC + LPS): treated with an oral dose of 30 mg/kg of PTX, followed by an IM dose of 20 mg/kg of FFC, and, 45 min after an IV dose of 5 µg/kg of LPS was administered. The anti-inflammatory response was evaluated through changes in plasma levels of interleukins (TNF-α, IL-1β and IL-6), C-reactive protein (CRP), and body temperature.

resultsIt has been shown that each drug produced a partial inhibition over the LPS-induced increase in TNF-α, IL-1β, and CRP. When both drugs were co-administered, a synergistic inhibitory effect on the IL-1β and CRP plasma concentrations was observed, associated with a synergic antipyretic effect. However, the co-administration of PTX/FFC failed to modify the LPS-induced increase in the TNF-α plasma concentrations.

conclusionsWe concluded that the combination of FFC and PTX in our LPS sepsis models demonstrates immunomodulatory effects. An apparent synergistic effect was observed for the IL-1β inhibition, which peaks at three hours and then decreases. At the same time, each drug alone was superior in reducing TNF-α levels, while the combination was inferior. However, the peak of TNF-α in this sepsis model was at 12 h. Therefore, in rabbits plasma IL-1β and TNF-α could be regulated independently, thus, further research is needed to explore the effects of this combination over a more prolonged period.

Indexed as

antibioticsanti-inflammatorycytokinesdrug interactionsflorfenicolpentoxifylline

Identifiers

PMID37107001
PMCPMC10135147
OpenAlexW4360853167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.